Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 1:50:101524.
doi: 10.1016/j.eclinm.2022.101524. eCollection 2022 Aug.

Trends in characteristics of the recipients of new prescription stimulants between years 2010 and 2020 in the United States: An observational cohort study

Shannon Brumbaugh  1 , Wen Jan Tuan  2 , Alyssa Scott  1 , James R Latronica  3 , Curtis Bone  2
Affiliations

Trends in characteristics of the recipients of new prescription stimulants between years 2010 and 2020 in the United States: An observational cohort study

Shannon Brumbaugh et al. EClinicalMedicine. .

Abstract

Background: Stimulant prescriptions increased by 250% in the United States from 2006-2016 while diagnoses for ADHD minimally increased. There is insufficient data regarding who may be the recipients of these new stimulant prescriptions and safety of stimulants have come under scrutiny in some populations. We aim to describe trends in stimulant prescriptions across biopsychosocial patient level factors between 2010 and 2020.

Methods: We applied a retrospective observational cohort design utilizing electronic health records from 52 healthcare organizations sourced from the TriNetX research network database in the United States. We assessed new stimulant prescriptions across biopsychosocial variables for recipients of prescriptions. We utilized linear regression to assess longitudinal trends of all participants and also conducted an age stratified logistic regression analysis.

Findings: There was an increase in stimulants to people categorized as white (OR 1.24 CI 1.20-1.28), female (OR 1.28 CI 1.23-1.31), and to those with diagnosed anxiety disorders (OR 1.39 CI 1.35-1.44) as well as obesity (OR 1.34 CI 1.28-1.41). The average age of recipients increased throughout the study, and among people sixty-five and older, there was an increase in prescriptions to people with multiple cardiovascular risk factors.

Interpretation: Prescription stimulant dispensing may have liberalized during the study period in some demographics as a greater number of new prescriptions were dispensed to individuals with risk of adverse outcomes (i.e. older individuals, obese individuals, and geriatric patients with CV risk factors) between 2010 and 2020. Similar trends in prescription medications were witnessed through the opioid epidemic and warrant attention given concerning trends with illicit stimulants. Additional research that investigates patient and provider motivation for stimulant prescriptions, as well as risk perception of stimulants, may be warranted.

Funding: This study was made possible by institutional resources at Penn State Hershey Medical Center.

Keywords: ADHD; Amphetamines; Cardiovascular outcomes; Stimulants.

PubMed Disclaimer

Conflict of interest statement

Shannon Brumbaugh, Wen Jan Tuan DHA, Alyssa Scott, James R. Latronica, and Curtis Bone attest that that they have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Trends in biopsychosocial characteristics of patients newly prescribed an amphetamine in the United States from years 2010-2020. * Statistical significance (p < 0.05) AND Slope <1.0. † Statistical significance (p < 0.05) AND Slope >1.0.
Figure 1
Figure 1
Trends in biopsychosocial characteristics of patients newly prescribed an amphetamine in the United States from years 2010-2020. * Statistical significance (p < 0.05) AND Slope <1.0. † Statistical significance (p < 0.05) AND Slope >1.0.
Figure 2
Figure 2
Age stratified trends in biopsychosocial characteristics of patients newly prescribed an amphetamine in the United States in 2010 vs. 2020. ’10 refers to 2010 and ’20 refers to 2020.
Figure 2
Figure 2
Age stratified trends in biopsychosocial characteristics of patients newly prescribed an amphetamine in the United States in 2010 vs. 2020. ’10 refers to 2010 and ’20 refers to 2020.
See this image and copyright information in PMC

References

    1. Centers for Medicare and Medicaid Services. Stimulant and Related Medications: Use in Pediatric Patients. https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medi...; Published October 2015. Accessed 21 June 2021.
    1. Satel S, Nelson J. Stimulants in the treatment of depression: a critical overview - PubMed. J Clin Psychiatry. 1989;50(7):241–249. - PubMed
    1. Sassi K, Rocha N, Colpo G, John V, Teixeira A. Amphetamine use in the elderly: a systematic review of the literature. Curr Neuropharmacol. 2020;18(2):126–135. doi: 10.2174/1570159X17666191010093021. - DOI - PMC - PubMed
    1. Torgersen T, Gjervan B, Lensing M, Rasmussen K. Optimal management of ADHD in older adults. Neuropsychiatr Dis Treat. 2016;12:79–87. doi: 10.2147/NDT.S59271. - DOI - PMC - PubMed
    1. Lavretsky H, Reinlieb M, St Cyr N, Siddarth P, Ercoli L, Senturk D. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172(6):561–569. doi: 10.1176/APPI.AJP.2014.14070889. - DOI - PMC - PubMed

LinkOut - more resources